Disease · MONDO_0004979

asthma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. asthma. Diseases, record MONDO_0004979. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004979

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: asthma; Open Targets
Open Targets ID: MONDO_0004979; Open Targets
Other names: ASTHMA NOS W (AC) EXAC, Airway hyperreactivity, Asthma (disorder), Asthma NOS, Asthma NOS (disorder), Asthma unspecified, Asthma unspecified (disorder), Asthma, Bronchial, Asthma, unspecified type, with acute exacerbation, Asthma, unspecified type, without mention of status asthmaticus, Asthmas, Asthmatic, BA, BHR - Bronchial hyperreactivity, Bronchial Hyperreactivities, Bronchial asthma, Bronchial hyperreactivity, Bronchial hyperresponsiveness, Bronchial hypersensitivity, DUST PNEUMONOPATHY NEC, Exercise induced asthma, Exercise-induced asthma (disorder), Hyperreactive airway disease, Hyperreactive airways disease, Hyperreactivities, Bronchial, Hyperreactivity, Bronchial, Other forms of asthma, Pneumonopathy due to inhalation of other dust, Pneumopathy due to inhalation of other dust, Pneumopathy due to inhalation of other dust (disorder), Pneumopathy due to inhalation of other dust NOS, Pneumopathy due to inhalation of other dust NOS (disorder), chronic obstructive asthma, chronic obstructive asthma with acute exacerbation, chronic obstructive asthma with status asthmaticus; Open Targets
Disease Ontology: DOID:2841; Disease Ontology
MeSH: D001249; MeSH
NCI Thesaurus: C28397; NCI Thesaurus
Highest stage of its drugs: Approval, for 90 of its 423 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs423

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BUDESONIDE	CHEMBL1370	Small molecule	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	213	186	178	Drugs and targets
FLUTICASONE PROPIONATE	CHEMBL1473	Small molecule	Approval	DailyMed, EMA Human Drugs and PMDA	194	169	157	Drugs and targets
ALBUTEROL	CHEMBL714	Small molecule	Approval	DailyMed	109	107	106	Drugs and targets
FORMOTEROL	CHEMBL1256786	Small molecule	Approval	EMA Human Drugs and TTD	111	105	102	Drugs and targets
SALMETEROL	CHEMBL1263	Small molecule	Approval	EMA Human Drugs	104	100	97	Drugs and targets
MONTELUKAST	CHEMBL787	Small molecule	Approval	DailyMed and TTD	97	94	94	Drugs and targets
BECLOMETHASONE DIPROPIONATE	CHEMBL1200500	Small molecule	Approval	DailyMed, FDA and PMDA	88	82	82	Drugs and targets
FORMOTEROL FUMARATE	CHEMBL3989798	Small molecule	Approval	DailyMed, EMA Human Drugs and TTD	85	76	74	Drugs and targets
FLUTICASONE FUROATE	CHEMBL1676	Small molecule	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	68	57	57	Drugs and targets
OMALIZUMAB	CHEMBL1201589	Antibody	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	56	50	49	Drugs and targets

1 to 10 of 423

See all 423 drugs

Targets247

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRB2	Adrenergic receptor	42	Adrenergic receptor agonist; Beta-2 adrenergic receptor agonist; Beta-2 adrenergic receptor antagonist	Approval	https://conductscience.org/library/genes/154	Drugs and targets
NR3C1	Glucocorticoid receptor	30	Glucocorticoid receptor agonist; Glucocorticoid receptor modulator	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
CHRM3	Muscarinic acetylcholine receptor	14	Muscarinic acetylcholine receptor M3 agonist; Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor inhibitor	Approval	https://conductscience.org/library/genes/1131	Drugs and targets
PTGDR2	Prostaglandin D2 receptor 2	11	G protein-coupled receptor 44 antagonist	Phase 3	https://conductscience.org/library/genes/11251	Drugs and targets
PDE4A	Phosphodiesterase 4	10	Phosphodiesterase 4 inhibitor	Approval	https://conductscience.org/library/genes/5141	Drugs and targets
PDE4B	Phosphodiesterase 4	10	Phosphodiesterase 4 inhibitor	Approval	https://conductscience.org/library/genes/5142	Drugs and targets
PDE4C	Phosphodiesterase 4	10	Phosphodiesterase 4 inhibitor	Approval	https://conductscience.org/library/genes/5143	Drugs and targets
PDE4D	Phosphodiesterase 4	10	Phosphodiesterase 4 inhibitor	Approval	https://conductscience.org/library/genes/5144	Drugs and targets
ADRB1	Adrenergic receptor	6	Adrenergic receptor agonist; Beta-1 adrenergic receptor antagonist	Approval	https://conductscience.org/library/genes/153	Drugs and targets
HRH1	Histamine H1 receptor	6	Histamine H1 receptor antagonist	Phase 3	https://conductscience.org/library/genes/3269	Drugs and targets

1 to 10 of 247

See all 247 targets

Trials1,387

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 52 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01347060	Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy		17,448	2011-06-01	Asthma	FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE, TRIAMCINOLONE	Its record names the disease	ClinicalTrials.gov
NCT01444430	A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents	Phase 3	12,460	2016-12-15	Asthma	BUDESONIDE, FORMOTEROL	Its record names the disease	ClinicalTrials.gov
NCT01475721	SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.	Phase 4	11,751	2016-01-14	Asthma	FLUTICASONE PROPIONATE, SALMETEROL	Its record names the disease	ClinicalTrials.gov
NCT01471340	A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)	Phase 4	11,744	2018-01-05	Asthma	FORMOTEROL, MOMETASONE FUROATE	Its record names the disease	ClinicalTrials.gov
NCT01328964	Comparison of Asthma-related Outcomes and Costs in Pediatric Subjects That Received Fluticasone Propionate, Budesonide or Montelukast in a Large Managed Care Population		9,906	2011-05-05	Asthma	BUDESONIDE, FLUTICASONE PROPIONATE, MONTELUKAST	Its record names the disease	ClinicalTrials.gov
NCT00463866	Local Phase 4 Pan-European SMART Study	Phase 4	8,424	2010-03-22	Asthma	BUDESONIDE, FORMOTEROL	Its record names the disease	ClinicalTrials.gov
NCT03964220	Impact of Tiotropium Add-on Therapy in Patients With Asthma		7,857	2020-10-12	Asthma	TIOTROPIUM	Its record names the disease	ClinicalTrials.gov
NCT01462344	6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old	Phase 4	6,250	2016-10-05	Asthma	FLUTICASONE PROPIONATE, SALMETEROL	Its record names the disease	ClinicalTrials.gov
NCT01332357	Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit		6,139	2011-10-13	Asthma	FLUTICASONE PROPIONATE, SALMETEROL	Its record names the disease	ClinicalTrials.gov
NCT01706198	An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma	Phase 3	4,233	2019-01-24	Asthma	FLUTICASONE FUROATE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 1,387

See all 1,387 trials

Comparisons in its trials458

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
MF/F MDI BID vs MF MDI BID: deaths from any cause	5 of 5,868	4 of 5,861	11,729	NCT01471340	Trial comparisons
MF/F MDI BID vs MF MDI BID: serious adverse events	136 of 5,868	137 of 5,861	11,729	NCT01471340	Trial comparisons
Symbicort vs Budesonide: Number of Participants Experiencing an Event in the Composite Endpoint (Asthma-related Death, Asthma-related Intubation or Asthma-related Hospitalization)	43 of 5,846	40 of 5,847	11,693	NCT01444430	Trial comparisons
Symbicort vs Budesonide: Number of Participants Experiencing Discontinuation of Investigational Product Due to a Protocol Defined Asthma Exacerbation	53 of 5,846	71 of 5,847	11,693	NCT01444430	Trial comparisons
Symbicort vs Budesonide: Number of Participants Experiencing an Event Included in the Definition of Asthma Exacerbation	539 of 5,846	633 of 5,847	11,693	NCT01444430	Trial comparisons
Symbicort vs Budesonide: serious adverse events	125 of 5,846	123 of 5,847	11,693	NCT01444430	Trial comparisons
Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP): Number of Participants Experiencing at Least One Asthma Exacerbation	480 of 5,834	597 of 5,845	11,679	NCT01475721	Trial comparisons
Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP): Number of Participant Withdrawals From Study Treatment Due to Asthma Exacerbation	66 of 5,834	84 of 5,845	11,679	NCT01475721	Trial comparisons
Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP): Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death)	34 of 5,834	33 of 5,845	11,679	NCT01475721	Trial comparisons
Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP): serious adverse events	134 of 5,834	125 of 5,845	11,679	NCT01475721	Trial comparisons

1 to 10 of 458

See all 458 comparisons in its trials

Papers from its trials852

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42052244	RESULT	1	PubMed
41304949	RESULT	1	PubMed
40645348	RESULT	1	PubMed
37914234	RESULT	1	PubMed
37878325	RESULT	1	PubMed
37876758	RESULT	1	PubMed
37343842	RESULT	1	PubMed
37003355	RESULT	1	PubMed
35569035	RESULT	1	PubMed
34779751	RESULT	1	PubMed

1 to 10 of 852

See all 852 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004979

GET https://conductscience.org/api/diseases/v1/MONDO_0004979/drugs?page=2

API reference For AI assistants